TABLE 2. Clinical manifestations of persons with probable or confirmed mpox, by JYNNEOS vaccination status — United States, May 2022–May 2024.
| Characteristic | No. (%) |
Odds ratio (95% CI) | p-value† | |
|---|---|---|---|---|
| Fully vaccinated* n = 271 | Unvaccinated n = 24,507 | |||
|
Outcomes
| ||||
|
Hospitalized because of mpox
| ||||
| No |
209 (98.6) |
18,054 (91.6) |
0.2 (0.0–0.5) |
<0.001§ |
| Yes |
3 (1.4) |
1,662 (8.4) |
||
| Unknown or missing |
59 |
4,791 |
||
|
Death due to mpox
| ||||
| No |
116 (100.0) |
13,521 (99.6) |
Not tested |
Not tested |
| Yes |
0 (—) |
56 (0.4) |
||
| Unknown or missing |
155 |
10,930 |
||
|
Systemic illness
¶
| ||||
| No |
36 (28.3) |
915 (12.3) |
0.4 (0.2–0.5) |
<0.001 |
| Yes |
91 (71.7) |
6,514 (87.7) |
||
| Unknown or missing |
144 |
17,078 |
||
|
Fever
| ||||
| No |
90 (61.6) |
4,283 (36.6) |
0.4 (0.3–0.5) |
<0.001 |
| Yes |
56 (38.4) |
7,412 (63.4) |
||
| Unknown or missing |
125 |
12,812 |
||
|
Headache
| ||||
| No |
96 (66.2) |
5,932 (47.5) |
0.5 (0.3–0.7) |
<0.001 |
| Yes |
49 (33.8) |
6,559 (52.5) |
||
| Unknown or missing |
126 |
12,016 |
||
|
Lymphadenopathy
| ||||
| No |
83 (57.2) |
4,963 (47.1) |
0.7 (0.5–0.9) |
0.02 |
| Yes |
62 (42.8) |
5,583 (52.9) |
||
| Unknown or missing |
126 |
13,961 |
||
|
Vomiting
| ||||
| No |
124 (91.9) |
7,313 (81.8) |
0.4 (0.2–0.7) |
0.004 |
| Yes |
11 (8.1) |
1,631 (18.2) |
||
| Unknown or missing |
136 |
15,563 |
||
|
Abdominal pain
| ||||
| No |
128 (94.1) |
9,330 (86.2) |
0.4 (0.2–0.8) |
0.01 |
| Yes |
8 (5.9) |
1,495 (13.8) |
||
| Unknown or missing |
135 |
13,682 |
||
|
Myalgia
| ||||
| No |
98 (70.0) |
5,129 (48.0) |
0.4 (0.3–0.6) |
<0.001 |
| Yes |
42 (30.0) |
5,555 (52.0) |
||
| Unknown or missing |
131 |
13,823 |
||
|
Chills
| ||||
| No |
93 (66.0) |
5,456 (42.4) |
0.4 (0.3–0.5) |
<0.001 |
| Yes |
48 (34.0) |
7,414 (57.6) |
||
| Unknown or missing |
130 |
11,637 |
||
|
Malaise
| ||||
| No |
69 (47.6) |
4,097 (38.0) |
0.7 (0.5–0.9) |
0.02 |
| Yes |
76 (52.4) |
6,685 (62.0) |
||
| Unknown or missing |
126 |
13,725 |
||
|
Other symptoms
| ||||
|
No. of anatomic locations with rash, median (IQR)
|
1 (1–2) |
4 (2–6) |
— |
<0.001** |
| Unknown or missing |
183 |
10,935 |
||
|
Genital rash
| ||||
| No |
29 (33.0) |
7,161 (52.8) |
2.3 (1.4–3.7) |
0.003 |
| Yes |
59 (67.0) |
6,411 (47.2) |
||
| Unknown or missing |
183 |
10,935 |
||
|
Rash
| ||||
| No |
9 (5.1) |
375 (2.7) |
0.5 (0.3–1.2) |
0.09 |
| Yes |
168 (94.9) |
13,293 (97.3) |
||
| Unknown or missing |
94 |
10,839 |
— |
|
|
Rectal pain
| ||||
| No |
90 (61.6) |
6,489 (63.2) |
1.1 (0.7–1.5) |
0.8 |
| Yes |
56 (38.4) |
3,780 (36.8) |
||
| Unknown or missing |
125 |
14,238 |
||
|
Proctitis
| ||||
| No |
121 (91.0) |
6,762 (85.1) |
0.6 (0.3–1.0) |
0.08 |
| Yes |
12 (9.0) |
1,186 (14.9) |
||
| Unknown or missing |
138 |
16,559 |
||
|
Rectal bleeding
| ||||
| No |
112 (80.0) |
7,350 (79.1) |
1.1 (0.7–1.7) |
0.9 |
| Yes |
28 (20.0) |
1,945 (20.9) |
||
| Unknown or missing |
131 |
15,212 |
||
|
Pus in stool
| ||||
| No |
117 (84.2) |
7,389 (82.4) |
0.9 (0.5–1.4) |
0.7 |
| Yes |
22 (15.8) |
1,578 (17.6) |
||
| Unknown or missing |
132 |
15,540 |
||
|
Tenesmus
| ||||
| No |
113 (81.9) |
7,736 (82.3) |
1.0 (0.6–1.6) |
1.0¶ |
| Yes |
25 (18.1) |
1,669 (17.7) |
||
| Unknown or missing |
133 |
15,102 |
||
|
Conjunctivitis
| ||||
| No |
117 (95.9) |
8,624 (95.5) |
0.9 (0.3–2.2) | 1.0 |
| Yes |
5 (4.1) |
405 (4.5) |
||
| Unknown or missing | 149 | 15,478 | ||
* Probable or confirmed cases in persons who received 2 JYNNEOS doses, with the most recent dose received ≥14 days before illness onset and with vaccination dates occurring since May 2022.
† Chi-square test p-value except where noted; p<0.05 was considered statistically significant.
§ Fisher’s exact test p-value.
¶ Systemic illness includes the presence of fever, headache, lymphadenopathy, vomiting, abdominal pain, myalgia, chills, or malaise.
** Wilcoxon rank-sum test p-value.